Biomaterial Manufacturing Suite in Support of NIH/NIAID and the Global Infectious Disease Research Community

支持 NIH/NIAID 和全球传染病研究界的生物材料制造套件

• 批准号: 10795293
• 负责人: Rebecca Bradford
• 金额: $ 479.83万
• 依托单位: AMERICAN TYPE CULTURE COLLECTION
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-09-06 至 2026-11-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10795293
• 关键词: Acceleration; American Type Culture Collection; Biocompatible Materials; Biological; Biological Products; COVID-19 pandemic; Communities; Containment; Development; Disease Outbreaks; Federal Government; Funding; Goals; Growth; Health; Human; Infectious Diseases Research; Longevity; Modernization; National Institute of Allergy and Infectious Disease; Nonprofit Organizations; Organism; Pathogenicity; Production; Public Health; Reproducibility; Research; Resources; Translational Research; United States National Institutes of Health; Variant; Virginia; cost; design; design and construction; detection assay; epidemic potential; manufacture; manufacturing capabilities; medical countermeasure; pandemic potential; priority pathogen; programs; service programs; therapeutic development; vaccine development

Biomaterial Manufacturing Suite in Support of NIH/NIAID and the Global Infectious Disease Research Community PROJECT DIRECTOR: REBECCA BRADFORD, MBA, MS, PMP® Project Summary The project is to construct and commission a Biomaterial Manufacturing Suite (BMS) as an expansion within the High Containment Facility (HCF) currently under design at the American Type Culture Collection (ATCC). ATCC is a non-profit entity in Manassas, Virginia, serving the Federal Government for over 50 years through our Federal Solutions (AFS) Division. The proposed aim of the BMS is to provide modern and reproducible large-scale biomaterial manufacturing capabilities for priority pathogens. Residing within the soon-to-be-built HCF, the BMS will offer the National Institute of Health and the National Institute of Allergy and Infectious Diseases (NIH/NIAID) high-throughput and rapid development pipelines for biomaterials of public health concern, including those of epidemic or pandemic potential. The BMS will directly support Federal Agencies and the infectious disease research communities by optimizing pathogenic organisms’ growth, production, and characterization for downstream use. By funding the BMS within the planned facility, AFS can enhance our support to NIH/NIAID through our ability to offer large-scale stocks of well-characterized challenge materials at no cost to the research community through AFS managed programs, including BEI Resources. In turn, this will accelerate infectious disease research for vaccine and therapeutic development in outbreak situations and serve as biological standards for developing detection assays. AFS’ current modular 7,500 ft2 HCF was built in 2007 as a temporary solution to facilitate the expanding needs of AFS’ Health and Human Services (HHS) programs. The facility is now over- extended with respect to lifespan, capacity, and capabilities. AFS dutifully maintains the upkeep of the current HCF to support the extensive NIH/NIAID requests for biological products to advance our medical countermeasures and arsenal against variants for the recent onslaught of the COVID- 19 pandemic. As a non-profit organization, ATCC has committed several million dollars to design and construct a new HCF to enhance and modernize our support to NIH. The explicit goal of this funding is to include the design, construction, and commissioning of the BMS within the facility footprint to provide critical biological manufacturing capabilities in the biomedical space to accelerate translational research for vaccine and therapeutic development.

支持NIH/NIAID和全球传染病管理局的生物材料制造套件 疾病研究社区 项目总监：丽贝卡·布拉德福德，MBA，MS，PMP® 项目摘要 该项目是建设和委托一个生物材料制造套件（BMS）作为一个 目前正在美国设计的高安全壳设施（HCF）内的扩建 典型培养物保藏中心（ATCC）。ATCC是弗吉尼亚州马纳萨斯的一个非营利实体， 通过我们的联邦解决方案（AFS）部门，为联邦政府服务了50多年。的 BMS的拟议目标是提供现代和可再生的大规模生物材料 重点病原体的生产能力。位于即将建成的HCF内， BMS将为国家卫生研究所和国家过敏和传染病研究所提供 疾病（NIH/NIAID）公共生物材料的高通量和快速开发管道 健康问题，包括流行病或可能大流行病问题。BMS将直接支持 联邦机构和传染病研究团体通过优化病原体 生物体的生长、生产和表征，以供下游使用。通过资助房舍管理处 在计划的设施内，美国战地服务团可以通过我们的能力， 大规模储存特性良好的挑战材料，研究界无需支付任何费用 通过AFS管理的计划，包括BEI资源。反过来，这将加速传染性 疾病研究，以便在爆发情况下开发疫苗和治疗方法， 用于开发检测分析的生物标准。 AFS目前的模块化7，500 ft 2 HCF建于2007年，作为临时解决方案，以促进 美国战地服务团的卫生和人类服务（HHS）方案的需求不断扩大。该设施现已结束- 在寿命、容量和能力方面延长。AFS尽职尽责地维护着 目前的HCF，以支持广泛的NIH/NIAID生物制品的要求，以推进 我们的医疗对策和武器库针对最近的新冠病毒袭击的变种- 19大流行病。作为一个非营利组织，ATCC已承诺数百万美元的设计， 并建立一个新的HCF，以加强和现代化我们对NIH的支持。这一行动的明确目标 资金将包括设施内BMS的设计、建造和调试 足迹，以提供关键的生物制造能力，在生物医学领域， 加速疫苗和治疗开发的转化研究。